Infusion Experience

2 doses a year, 2 more reasons to
choose UPLIZNA1

UPLIZNA patient, Jasmine

Twice-yearly dosing with UPLIZNA offers patients more infusion-free time1

UPLIZNA patient, Jasmine

Graphic showing the UPLIZNA dosing schedule, with initial doses on Day 1 and Day 15 and maintenance dosing every 6 months after the first doseGraphic showing the UPLIZNA dosing schedule, with initial doses on Day 1 and Day 15 and maintenance dosing every 6 months after the first dose

6-month maintenance infusions of only 90 minutes each1

  • UPLIZNA is a 300 mg intravenous infusion1
  • Check IgG levels and test for hepatitis B virus and tuberculosis prior to treatment administration1
  • Administer all recommended vaccinations at least 4 weeks prior to initiation of UPLIZNA1
  • A corticosteroid, an antihistamine, and an antipyretic are given 30 to 60 minutes prior to administration to reduce infusion reactions1,2
Treatment Comparison Among UPLIZNA and Other FDA-approved Therapies
UPLIZNA®
(inebilizumab-cdon)		 SOLIRIS®3
(eculizumab)		 ENSPRYNG®4
(satralizumab-mwge)
Mechanism of action CD19+ B-cell depletion Complement inhibition (anti-C5) Anti-IL-6R
Initial dose 2 doses, 2 weeks apart 5 doses, 1 week apart 3 doses, 2 weeks apart
Maintenance dose Every 6 months
(~2 doses per year)		 Every 2 weeks
(~24 doses per year)		 Every 4 weeks
(~12 doses per year)
Mode of administration IV infusion IV infusion SC injection
Mechanism of action UPLIZNA®
(inebilizumab-cdon) 		CD19+ B-cell
depletion		 SOLIRIS®3
(eculizumab) 		Complement
Inhibitor (anti-C5)		 ENSPRYNG®4
(satralizumab-mwge) 		Anti-IL-6R
Initial dose UPLIZNA®
(inebilizumab-cdon) 		2 doses,
2 weeks apart		 SOLIRIS®3
(eculizumab) 		5 doses,
1 week apart		 ENSPRYNG®4
(satralizumab-mwge) 		3 doses,
2 weeks apart
Maintenance dose UPLIZNA®
(inebilizumab-cdon) 		Every 6 months
(~2 doses per year)		 SOLIRIS®3
(eculizumab) 		Every 2 weeks
(~24 doses per year)		 ENSPRYNG®4
(satralizumab-mwge) 		Every 4 weeks
(~12 doses per year)
Mode of administration UPLIZNA®
(inebilizumab-cdon) 		IV infusion SOLIRIS®3
(eculizumab) 		IV infusion ENSPRYNG®4
(satralizumab-mwge) 		SC injection
Access and support icon

Access and Support

Learn about Horizon By Your Side, a personalized support program for your patients.

Find Support For Your Patients
Stay connected icon

Stay Up to Date

Get the latest UPLIZNA information and resources as soon as they are available.

Sign Up Now

Learn about patient access and support

AE, adverse event; IgG, immunoglobulin G; NMOSD, neuromyelitis optica spectrum disorder; SC, subcutaneous.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

UPLIZNA (inebilizumab-cdon) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

IMPORTANT SAFETY INFORMATION

UPLIZNA is contraindicated in patients with:

  • A history of life-threatening infusion reaction to UPLIZNA
  • Active hepatitis B infection
  • Active or untreated latent tuberculosis

WARNINGS AND PRECAUTIONS

Infusion Reactions: UPLIZNA can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash, or other symptoms. Infusion reactions were most common with the first infusion but were also observed during subsequent infusions. Administer pre-medication with a corticosteroid, an antihistamine, and an anti-pyretic.

Infections: The most common infections reported by UPLIZNA-treated patients in the randomized and open-label periods included urinary tract infection (20%), nasopharyngitis (13%), upper respiratory tract infection (8%), and influenza (7%). Delay UPLIZNA administration in patients with an active infection until the infection is resolved.

Increased immunosuppressive effects are possible if combining UPLIZNA with another immunosuppressive therapy.

The risk of Hepatitis B Virus (HBV) reactivation has been observed with other B-cell-depleting antibodies. Perform HBV screening in all patients before initiation of treatment with UPLIZNA. Do not administer to patients with active hepatitis.

Although no confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) were identified in UPLIZNA clinical trials, JC virus infection resulting in PML has been observed in patients treated with other B-cell-depleting antibodies and other therapies that affect immune competence. At the first sign or symptom suggestive of PML, withhold UPLIZNA and perform an appropriate diagnostic evaluation.

Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating UPLIZNA.

Vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation, until B-cell repletion.

Reduction in Immunoglobulins: There may be a progressive and prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued UPLIZNA treatment. Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with UPLIZNA until B-cell repletion especially in patients with opportunistic or recurrent infections.

Fetal Risk: May cause fetal harm based on animal data. Advise females of reproductive potential of the potential risk to a fetus and to use an effective method of contraception during treatment and for 6 months after stopping UPLIZNA.

Adverse Reactions: The most common adverse reactions (at least 10% of patients treated with UPLIZNA and greater than placebo) were urinary tract infection and arthralgia.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

UPLIZNA (inebilizumab-cdon) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

IMPORTANT SAFETY INFORMATION

UPLIZNA is contraindicated in patients with:

  • A history of life-threatening infusion reaction to UPLIZNA
  • Active hepatitis B infection
  • Active or untreated latent tuberculosis

WARNINGS AND PRECAUTIONS

Infusion Reactions: UPLIZNA can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash, or other symptoms. Infusion reactions were most common with the first infusion but were also observed during subsequent infusions. Administer pre-medication with a corticosteroid, an antihistamine, and an anti-pyretic.

Infections: The most common infections reported by UPLIZNA-treated patients in the randomized and open-label periods included urinary tract infection (20%), nasopharyngitis (13%), upper respiratory tract infection (8%), and influenza (7%). Delay UPLIZNA administration in patients with an active infection until the infection is resolved.

Increased immunosuppressive effects are possible if combining UPLIZNA with another immunosuppressive therapy.

The risk of Hepatitis B Virus (HBV) reactivation has been observed with other B-cell-depleting antibodies. Perform HBV screening in all patients before initiation of treatment with UPLIZNA. Do not administer to patients with active hepatitis.

Although no confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) were identified in UPLIZNA clinical trials, JC virus infection resulting in PML has been observed in patients treated with other B-cell-depleting antibodies and other therapies that affect immune competence. At the first sign or symptom suggestive of PML, withhold UPLIZNA and perform an appropriate diagnostic evaluation.

Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating UPLIZNA.

Vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation, until B-cell repletion.

Reduction in Immunoglobulins: There may be a progressive and prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued UPLIZNA treatment. Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with UPLIZNA until B-cell repletion especially in patients with opportunistic or recurrent infections.

Fetal Risk: May cause fetal harm based on animal data. Advise females of reproductive potential of the potential risk to a fetus and to use an effective method of contraception during treatment and for 6 months after stopping UPLIZNA.

Adverse Reactions: The most common adverse reactions (at least 10% of patients treated with UPLIZNA and greater than placebo) were urinary tract infection and arthralgia.

  1. UPLIZNA (inebilizumab-cdon) [prescribing information]. Horizon.
  2. Cree BAC, Bennett JL, Kim HJ, et al; N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised, placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352-1363. doi:10.1016/S0140-6736(19)31817-3
  3. SOLIRIS® (eculizumab) [prescribing information]. Alexion Pharmaceuticals, Inc.
  4. ENSPRYNG® (satralizumab-mwge) [prescribing information]. Genentech, Inc.